Back to News
Market Impact: 0.25
Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion
Source: benzinga.com
Healthcare & BiotechCompany FundamentalsTechnology & InnovationPatents & Intellectual Property
Medicus Pharma (MDCX) secured an exclusive, sublicensable global license from Pfizer (PFE) to develop, manufacture, and commercialize PF-08046031 (CD228V), an early clinical-stage antibody-drug conjugate targeting melanotransferrin. The deal gives MDCX full development/commercial rights, which is a positive strategic step though PF-08046031 remains in early-stage development.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
MDCX0.60
PFE0.20
More News
- Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?
- Bending Spoons wants to revive software castoffs. Berkshire is backing the plan
- AI rapidly improving, could vastly boost U.S. GDP, Anthropic's Clark tells policymakers
- ‘How many canaries have we killed in the coal mine?’ — Wall Street debates if the latest AI bubble warnings are another head fake or the real thing
- Semiconductor market to remain solid ‘at least through next year,’ South Korea finance minister says
- Nasdaq Index: AI Selloff Deepens as Chips and CoreWeave Break
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI for Sell-Side Models, Estimates, and Internal Data
- How to Write an Investment Memo with AI: A Decision-Record Template